Fc Receptor-like 5, Recombinant, Human (FCRL5, FcRH5)
Catalog No : USB-F0025-77
682.78€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Fc Receptor-like 5, Recombinant, Human (FCRL5, FcRH5) | ||
|---|---|---|---|
| Catalog No | USB-F0025-77 | ||
| Supplier’s Catalog No | F0025-77 | ||
| Supplier | US Biologicals | ||
| Source antigen | Recombinant, Murine myeloma cell line | ||
| Reactivity | |||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 91.5 | ||
| Storage | -70°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Highly Purified | ||
| Purity | ≥95% (SDSPAGE) | ||
| Form | Supplied as a lyophilized powder from 0.2um filtered solution in PBS. Reconstitute with sterile 100ug/ml PBS. | ||
| Reactivity life | 6 months | ||
| Note | For reserch purpose only | ||
| Purity | ≥95% (SDSPAGE) | ||
| Description | Fc Receptor-Like 5 (FCRL5), also known as FcRH5, IRTA2, and CD307, is a 120kD protein with sequence homology to classical Fc receptors. The type 1 transmembrane FCRL proteins contain from three to nine immunoglobulin-l i ke domains. They are differentially expressed within the B cell lineage and can either promote or inhibit B cell proliferation and activation. According to testing, FCRL5 binds to purified human IgG with high affinity. Mature human FCRL5 consists of a 836aa extracellular domain (ECD) with nine Ig-like domains, a 21aa transmembrane segment, and a 105aa cytoplasmic domain with one immunotyrosine activation motif (ITAM) and two immunotyrosine inhibitory motifs (ITIMs). Mouse FCRL5 contains only five Ig-like domains in its ECD. It shares 49% aa sequence identity with human FCRL5 within common regions. Alternate splicing of human FCRL5 generates isoforms that consist of approximately the first one, six, or eight Ig-like domains. FCRL5 expression is restricted to mature B lineage cells in lymphoid tissues and blood. Its ligation inhibits signaling through the B cell antigen receptor. Epstein-Barr virus transformation of B cells induces the upregulation of surface FCRL5 by a direct effect of its EBNA2 protein on FCRL5 gene transcription. The FCRL5 gene maps to the 1q21 chromosomal locus, a common site of rearrangements in B cell malignancies, and the FCRL5 protein is preferentially expressed in cell lines with 1q21 abnormalities. FCRL5 is upregulated on tumor cells in some types of B cell malignancies. In addition, soluble FCRL5 is elevated in the serum of many B cell leukemia patients. Source: Murine myeloma cell line, NS0derived Gln16-Arg844, with a C-terminal 6-His tag SDS-PAGE: 110-120kD, reducing conditions. Biological Activity: Measured by its ability to bind human IgG with an estimated KD<30nM. Endotoxin: ≤1EU/ug (LAL) Storage and Stability: Lyophilized powder may be stored at -70°C. Reconstitute with sterile buffer or ddH2O. Aliquot and store at -70°C. Reconstituted product is stable for 6 months at -70°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. | ||
Product Details
© 2020 Imugex All Rights Reserved